6.
Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S
. SOAPnuke: a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data. Gigascience. 2017; 7(1):1-6.
PMC: 5788068.
DOI: 10.1093/gigascience/gix120.
View
7.
Wang Y, Wu J, Chen H, Yang Y, Xiao C, Yi X
. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells. Sci Adv. 2021; 7(5).
PMC: 7840125.
DOI: 10.1126/sciadv.abe3445.
View
8.
Li H, Song F, Duan L, Sheng J, Xie Y, Yang Q
. Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: Roles of Nrf2/HO-1 and PI3K/Akt pathway. Sci Rep. 2016; 6:23693.
PMC: 4810373.
DOI: 10.1038/srep23693.
View
9.
Ziblat A, Domaica C, Spallanzani R, Raffo Iraolagoitia X, Rossi L, Avila D
. IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol. 2014; 45(1):192-202.
DOI: 10.1002/eji.201444699.
View
10.
Faranoush P, Jahandideh A, Nekouian R, Mortazavi P
. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research. Vet Med Sci. 2023; 9(3):1426-1437.
PMC: 10188073.
DOI: 10.1002/vms3.1109.
View
11.
Altman T, Travers M, Kothari A, Caspi R, Karp P
. A systematic comparison of the MetaCyc and KEGG pathway databases. BMC Bioinformatics. 2013; 14:112.
PMC: 3665663.
DOI: 10.1186/1471-2105-14-112.
View
12.
Li P, Chen C, Li S, Givi B, Yu Z, Zamarin D
. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck. 2011; 33(10):1394-9.
PMC: 3116983.
DOI: 10.1002/hed.21609.
View
13.
Lorence R, Katubig B, Reichard K, Reyes H, Phuangsab A, Sassetti M
. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994; 54(23):6017-21.
View
14.
Pecora A, Rizvi N, Cohen G, Meropol N, Sterman D, Marshall J
. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002; 20(9):2251-66.
DOI: 10.1200/JCO.2002.08.042.
View
15.
Jin Z, El-Deiry W
. Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4(2):139-63.
DOI: 10.4161/cbt.4.2.1508.
View
16.
Zamarin D, Palese P
. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012; 7(3):347-67.
PMC: 4241685.
DOI: 10.2217/fmb.12.4.
View
17.
Song D, Liang Y, Xiao Q, Yin J, Gong J, Lai Z
. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro. Anat Rec (Hoboken). 2013; 296(10):1552-60.
DOI: 10.1002/ar.22768.
View
18.
Langmead B, Trapnell C, Pop M, Salzberg S
. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25.
PMC: 2690996.
DOI: 10.1186/gb-2009-10-3-r25.
View
19.
Yuan P, Paterson R, Leser G, Lamb R, Jardetzky T
. Structure of the ulster strain newcastle disease virus hemagglutinin-neuraminidase reveals auto-inhibitory interactions associated with low virulence. PLoS Pathog. 2012; 8(8):e1002855.
PMC: 3415446.
DOI: 10.1371/journal.ppat.1002855.
View
20.
Chen M, Xu R, Ji H, Greening D, Rai A, Izumikawa K
. Transcriptome and long noncoding RNA sequencing of three extracellular vesicle subtypes released from the human colon cancer LIM1863 cell line. Sci Rep. 2016; 6:38397.
PMC: 5137021.
DOI: 10.1038/srep38397.
View